We are the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS. Learn more >
Our sites conduct all phases of clinical trials - from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Learn more >
Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development. Learn more >
The first in a series of clinical trials designed to build on the promise of an HIV vaccine that showed modest protection when tested in Thailand has passed a key hurdle, according to a new study. It paves the way for larger HIV vaccine trials to move forward in South Africa.
The trial found that the so-called Thai vaccine induced comparable immune responses when tested in South Africa as it had in the original trial. This early phase of testing was designed to see how a different population’s immune system would respond, not—yet—whether the vaccine would protect against HIV.
Antibodies that are able to adhere to the outer shell of HIV can inactivate the virus, and potentially stop infection before it starts. However, HIV is one of the most changeable viruses discovered to date, and the strains in circulation vary widely. An ideal vaccine against HIV would produce antibodies that could inactivate all HIV strains, but the reality is that antibodies against one strain usually don’t work against others. Read more >
We support the next generation of HIV researchers with structured mentoring, projects, training, and networking opportunities. Learn more >
Getting the right test will prevent an incorrect diagnosis of HIV. Your study site or VISP Testing Service can provide the right test. Visit our frequently asked questions for more information.